drugset / Trial / NCT05429294
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the efficacy and safety of pyrotinib combined with trastuzumab and albumin paclitaxel in first-line treatment of HER2-positive advanced or metastatic breast cancer.
Timeline
- Start
- 2022-06-01
- Primary completion
- 2024-05-31
- Completion
- 2024-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albumin paclitaxel | Unknown | — | — |
| Subject | Pyrotinib | Small molecule | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |